{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:03:16Z","timestamp":1789966996092,"version":"4.0.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study assesses the serum levels of Elabela (ELA\/Apela) and apelin receptor (APJ), angiotensin II (Ang II) and angiotensin-converting enzyme (ACE), as well as Ang (1\u20137) and ACE2, in patients with acute heart failure (AHF) and type I cardiorenal syndrome (CRS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 31 AHF patients, 38 type I CRS patients and 31 healthy controls were enrolled. Serum concentrations of ELA, APJ, Ang II, ACE, Ang (1-7) and ACE2 were measured using ELISA. ROC curves were used to assess the diagnostic performance of the ratios of Ang (1-7)\/Ang II and ELA\/Ang II for AHF and type I CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean ratios of Ang (1-7)\/Ang II and ELA\/Ang II increased in both AHF and CRS groups compared to the control group. However, the ratio of ELA\/Ang II significantly decreased in the CRS group compared to the AHF group. The ratio of ELA\/Ang II negatively correlated with creatinine and positively correlated with eGFR in CRS patients. The AUC for Ang (1-7)\/Ang II in diagnosing AHF and type I CRS was 0.7128 and 0.6978, respectively. The AUC for ELA\/Ang II in diagnosing AHF and type I CRS was 0.8783 and 0.7530, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ELA\/Ang II ratio can be used as an additional indicator for diagnosing AHF or type I CRS. Although the ELA\/Ang II ratio is particularly well correlated with eGFR in patients with type I CRS, the value of the ratio in evaluating the degree of renal impairment in these patients remains to be further studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1912581","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:05Z","timestamp":1789964885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential expression and clinical significance of angiotensin (1-7)\/Ang II and Elabela\/Ang II ratios in patients with acute heart failure and type I cardiorenal syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengdi","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Physical Diagnosis, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Fourth Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104285","DOI":"10.1016\/j.drudis.2024.104285","article-title":"Novel therapeutic targets for cardiorenal syndrome","volume":"30","author":"Trivedi","year":"2025","journal-title":"Drug Discov Today"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/CIRCRESAHA.122.319989","article-title":"Cardiorenal syndrome: the role of neural connections between the heart and the kidneys","volume":"130","author":"Patel","year":"2022","journal-title":"Circ Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41401-025-01476-z","article-title":"Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies","volume":"46","author":"Zhao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/CRD.0000000000000532","article-title":"Acute cardiorenal syndrome: an update","volume":"32","author":"Sohal","year":"2024","journal-title":"Cardiol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e14134","DOI":"10.1111\/apha.14134","article-title":"Unraveling the crosstalk between renin-angiotensin system receptors","volume":"240","author":"Gironacci","year":"2024","journal-title":"Acta Physiol (Oxf)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"111426","DOI":"10.1016\/j.cellsig.2024.111426","article-title":"The renin-angiotensin-aldosterone system: an old tree sprouts new shoots","volume":"124","author":"Ruan","year":"2024","journal-title":"Cell Signal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics13010016","article-title":"A new perspective on the renin-angiotensin system","volume":"13","author":"Martyniak","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/jcm12216873","article-title":"The RAAS goodfellas in cardiovascular system","volume":"12","author":"Caputo","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2174\/1389450123666220826160123","article-title":"Elabela peptide: an emerging target in therapeutics","volume":"23","author":"Sharma","year":"2022","journal-title":"Curr Drug Targets"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107193","DOI":"10.1016\/j.vph.2023.107193","article-title":"Cardiovascular aspects of ELABELA: a potential diagnostic biomarker and therapeutic target","volume":"151","author":"Xu","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11333","DOI":"10.1038\/s41598-024-61480-x","article-title":"Decreased plasma ELABELA level as a novel screening indicator for heart failure: a cohort and observational study","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B13","first-page":"4467","article-title":"Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K\/AKT signaling","volume":"12","author":"Yu","year":"2020","journal-title":"Am J Transl Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-015-0521-6","article-title":"Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart","volume":"111","author":"Perj\u00e9s","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1631\/jzus.B2300033","article-title":"ELABELA-derived peptide ELA13 attenuates kidney fibrosis by inhibiting the smad and ERK signaling pathways","volume":"25","author":"Yan","year":"2024","journal-title":"J Zhejiang Univ Sci B"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.peptides.2019.04.005","article-title":"Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K\/akt\/mTOR pathway","volume":"114","author":"Zhang","year":"2019","journal-title":"Peptides"},{"key":"B17","doi-asserted-by":"publisher","first-page":"F1122","DOI":"10.1152\/ajprenal.00606.2019","article-title":"ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury","volume":"318","author":"Xu","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cvr\/cvx061","article-title":"ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage","volume":"113","author":"Sato","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). with the special contribution of the heart failure association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","article-title":"Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1\u20137)","volume":"292","author":"Grobe","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.freeradbiomed.2024.02.010","article-title":"Benzoylaconitine: a promising ACE2-targeted agonist for enhancing cardiac function in heart failure","volume":"214","author":"Zhang","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00380-016-0877-z","article-title":"Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1\u20137) concentration in patients with acute heart failure patients requiring emergency hospitalization","volume":"32","author":"Hisatake","year":"2017","journal-title":"Heart Vessels"},{"key":"B26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e006939","DOI":"10.1161\/CIRCHEARTFAILURE.120.006939","article-title":"Elevated angiotensin 1\u20137\/angiotensin II ratio predicts favorable outcomes in patients with heart failure","volume":"13","author":"Wang","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10382","DOI":"10.1111\/jcmm.15651","article-title":"Apela improves cardiac and renal function in mice with acute myocardial infarction","volume":"24","author":"Pan","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e21907","DOI":"10.1096\/fj.202101030R","article-title":"Apela inhibits systemic and renal inflammatory reactions in mice with type I cardiorenal syndrome","volume":"35","author":"Jin","year":"2021","journal-title":"Faseb j"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000536316","article-title":"Clinical significance of apela in acute cardiorenal insuffiency of chronic heart failure","volume":"49","author":"Zong","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1038\/srep08170","article-title":"Elabela-apelin receptor signaling pathway is functional in mammalian systems","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.7150\/thno.84308","article-title":"Tubular elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation","volume":"13","author":"Xiong","year":"2023","journal-title":"Theranostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10087","DOI":"10.3390\/ijms262010087","article-title":"The impact of the apelinergic system on the cardiovascular system","volume":"26","author":"Wyderka","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000033522.37861.69","article-title":"Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility","volume":"91","author":"Szokodi","year":"2002","journal-title":"Circ Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4314\/ahs.v20i2.37","article-title":"Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy?","volume":"20","author":"Onalan","year":"2020","journal-title":"Afr Health Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"123032","DOI":"10.1016\/j.lfs.2024.123032","article-title":"Apelinergic system in acute kidney injury: mechanistic insights and therapeutic potential","volume":"356","author":"Patil","year":"2024","journal-title":"Life Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:06Z","timestamp":1789964886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1912581"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1912581","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1912581"}}